Article
Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV.
The Lancet. Infectious diseases - 1 Nov 2005
Balzarini Jan
Abstract excerpt
The development of drug resistance in HIV compromises the long-term efficacy of current therapies. Furthermore, vaccine development faces huge problems, mainly because of the low antigenicity and immunogenicity of the HIV envelope glycoprotein gp120 and the efficient hiding of highly immunogenic epitopes by its glycans. There is evidence that mutant HIV strains containing glycosylation site deletions trigger the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
